Qiagen N.V. (QGEN) News
Track canonical SquawkNews coverage tagged to QGEN, Qiagen N.V.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 29 indexed stories across 15 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
QGEN: Growth, AI-driven automation, and disciplined capital allocation drive strong margin performance
Leadership emphasized growth, margin expansion, and commercial excellence, with AI and automation initiatives underway to drive efficiency and new product launches ramping through 2027. Market dynamics remain challenging
NEWS | Sep 14, 2026, 06:47 PM UTC
L
QIAGEN N.V. voting rights release under WpHG Article 40
Qiagen N.V. said the AFM informed it on September 5, 2026 of a voting-rights notification related to the institution. The company made the release under article 40 para. 1 WpHG (AFM).
REGULATION | Sep 09, 2026, 08:05 PM UTC
L
UBS cuts Qiagen price target, keeps rating neutral
UBS cut its Qiagen price target to $47.00 per share from $52.00 while maintaining a neutral rating, according to TradingView News via Benzinga.
EQUITY | Sep 09, 2026, 06:24 PM UTC
L
Qiagen managers’ transactions notification filed under Article 19 MAR
QIAGEN N.V. posted a managers’ transactions announcement according to Article 19 MAR. The notification concerns Jonathan M. Pratt and includes his position and the reason for reporting.
EQUITY | Sep 08, 2026, 08:10 PM UTC
L
Qiagen managers’ transactions disclosed under Article 19 MAR
Qiagen N.V. Investor Relations issued a managers’ transactions announcement under Article 19 MAR, dated Venlo (08.09.2026).
EQUITY | Sep 08, 2026, 08:10 PM UTC
L
Qiagen voting rights release filed with AFM under WpHG Article 40
Qiagen N.V. said the AFM informed it regarding a release of voting rights announcement under Article 40, paragraph 1 of the WpHG. The notice is dated Venlo (04.09.2026).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
Qiagen voting rights release filed via AFM notice
Qiagen N.V. issued a voting rights announcement release under Article 40 Section 1 of the WpHG, following an AFM notification. Dated Venlo (02.09.2026).
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
QIAGEN notified of voting rights announcement under WpHG Article 40
QIAGEN N.V. said the AFM informed it on August 29, 2026 of a notification related to the institution, published as a voting rights release under WpHG Article 40.
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
EQUITY | Aug 28, 2026, 09:23 PM UTC
L
QIAGEN N.V. files Article 40, Section 1 WpHG release
QIAGEN N.V. has issued a release under Article 40, Section 1 of the WpHG.
EQUITY | Aug 28, 2026, 08:05 PM UTC
L
Release according to Article 40, Section 1 of the WpHG
Release according to Article 40, Section 1 of the WpHG
EQUITY | Aug 28, 2026, 08:05 PM UTC
M
Jury awards $4.8M damages over Evercode sales
Jury awarded $4.8M in damages for sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026.
EQUITY | Aug 28, 2026, 06:41 PM UTC
M
10x Genomics jury finds Qiagen unit Parse Biosciences infringed
U.S. jury found a Qiagen unit infringed patents held by Parse Biosciences, per TradingView News.
EQUITY | Aug 28, 2026, 06:40 PM UTC
M
10x Genomics wins patent verdict against Parse Biosciences
10x Genomics won a patent infringement verdict against Parse Biosciences.
EQUITY | Aug 28, 2026, 06:39 PM UTC
L
TXG QGEN - 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
TXG QGEN - 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
EQUITY | Aug 28, 2026, 06:39 PM UTC
L
QGEN launches QIAsymphony Connect for automated clinical nucleic acid extraction
QGEN launched QIAsymphony Connect for automated clinical nucleic acid extraction.
EQUITY | Aug 27, 2026, 08:05 PM UTC
L
QGEN faces renewed M&A speculation
TradeXchange Newsdesk circulates M&A talk around QGEN, citing small-market circulations, without supplying deal terms or confirmation.
MNA | Aug 25, 2026, 06:54 PM UTC
L
QIAGEN appoints Jonathan M. Pratt CEO, reaffirms Q3 and FY26 guidance
QIAGEN N.V. appointed Jonathan M. Pratt chief executive officer effective September 1, 2026, succeeding Thierry Bernard, and reaffirmed its outlook for the third quarter and full-year 2026.
EQUITY | Aug 24, 2026, 01:51 PM UTC
L
Qiagen appoints Jonathan M. Pratt as chief executive officer
Qiagen N.V. appoints Jonathan M. Pratt as chief executive officer, effective September 1, 2026.
EQUITY | Aug 24, 2026, 01:48 PM UTC
H
Qiagen names Jonathan M. Pratt CEO effective September 1, 2026
Qiagen N.V. says Jonathan M. Pratt will become CEO effective September 1, 2026, and will be proposed as a managing director at an extraordinary general meeting planned for Q4 2026.
EQUITY | Aug 24, 2026, 01:46 PM UTC
L
Qiagen FY2026 Adj EPS expected to be more than $2.43 vs $2.42 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.139B Est
Qiagen (NYSE: QGEN ) FY2026 expected to be more than $2.43 vs $2.42 Est. affirms FY2026 sales outlook from $2.111 billion-$2.132 billion to $2.111 billion-$2.132 billion vs $2.139 billion estimate.
EARNINGS | Aug 05, 2026, 08:20 PM UTC
L
QGEN BMXXY New GeneXpert hints more competition pain for multiplex peers @ Exane
QGEN BMXXY New GeneXpert hints more competition pain for multiplex peers @ Exane
EQUITY | Jul 22, 2026, 01:43 PM UTC
L
QGEN qiagen highlights Molecular testing solutions supporting response to growing U.S. cyclospora outbreak
QGEN qiagen highlights Molecular testing solutions supporting response to growing U.S. cyclospora outbreak
EQUITY | Jul 15, 2026, 08:07 PM UTC
L
moves among today's downgrades IBM -23.4%, OI -6.9%, CRCL -4.1%, SLVM -3.7%, ARM -3.4%, IP -2.6%, PGR -2.3%, GEF -2.0%, TCBK -1.1%, PTRN -1.
moves among today's downgrades IBM -23.4%, OI -6.9%, CRCL -4.1%, SLVM -3.7%, ARM -3.4%, IP -2.6%, PGR -2.3%, GEF -2.0%, TCBK -1.1%, PTRN -1.0%, AAPL -1.0%, QGEN -0.9%, EQR -0.5%, AVB -0.5%, ELS -0.5%, TMHC +0.1%, EH +0.1
EQUITY | Jul 14, 2026, 01:52 PM UTC
L
QGEN downgraded form Buy to Hold W/ $45.50 PT (from $59) @ Berenberg
QGEN downgraded form Buy to Hold W/ $45.50 PT (from $59) @ Berenberg
EQUITY | Jul 14, 2026, 11:59 AM UTC
H
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Qiagen NV (NYSE: QGEN ) is drawing renewed investor attention after reports that several private equity firms are evaluating a potential takeover of the molecular diagnostics company. The stock surged 10.5% in the previo
MACRO | Jul 10, 2026, 01:26 PM UTC
M
Citi, MS, JPM Upgrade AHR, CDW, IBM
Citi, Morgan Stanley, JPMorgan, and others upgrade AHR, CDW, IBM, QGEN, SNPS, and TGT
EQUITY | Jun 23, 2026, 10:55 AM UTC
M
IBM, QGEN, SNPS Upgraded
IBM, QGEN, and SNPS have been upgraded to OVERWEIGHT by JPM, MS, and Piper respectively
EQUITY | Jun 23, 2026, 09:40 AM UTC